In-home evaluation of efficacy and titration of a mandibular advancement device for obstructive sleep apnea by Levendowski, Daniel J. et al.
ORIGINAL ARTICLE
In-home evaluation of efficacy and titration of a mandibular
advancement device for obstructive sleep apnea
Daniel J. Levendowski & Todd D. Morgan &
John E. Patrickus & Philip R. Westbrook & Chris Berka &
Timothy Zavora & Djordje Popovic
Published online: 18 January 2007
# Springer-Verlag 2007
Abstract There is increasing evidence that mandibular
advancement devices (MADs) can be an effective treatment
for some patients with obstructive sleep apnea, a highly
prevalent chronic disease. In this study, the objectives were
to objectively assess the effectiveness of MAD therapy
using a limited channel recorder, and to develop a model
for identifying patients who may be appropriate for MAD
therapy as the initial treatment option. Thirty patients were
prospectively recruited and studied at two independent
dentist offices and the participants’ homes. Subjects wore
the ARES Unicorder for two nights before insertion of the
MAD, and again when the dentist determined that the
patient had reached the titration endpoint. Self-reported
measures of depression, sleepiness, and quality of life were
obtained pre- and posttreatment. The reviewer was blinded
to the study status while the physiological signals were
being visually inspected. Significant reductions in the
apnea/hypopnea index (AHI), hypoxemia measures, and
snoring level were observed posttreatment. Twenty-seven
of the 30 (90%) patients had a posttreatment AHI (using a
4% desaturation for hypopneas) below a clinical cut-off of
10. All but one patient (97%) exhibited at least a 50%
decrease in AHI or had a posttreatment AHI≤10. Signifi-
cant differences in body mass index, weight, and neck
circumference in patients with posttreatment AHIs above
and below a clinical cut-off of five were identified. The
linear regression used to predict the posttreatment AHI
using pretreatment data resulted in an R
2 of 0.68. The
model correctly predicted two patients who were unable to
obtain a posttreatment AHI of 10 or less. This study was
designed to demonstrate two models of collaboration
between a dental sleep medicine specialist and a sleep
medicine physician in the monitoring of a patient treated
with a MAD. The outcome data suggest that the limited
channel recording system can be used as an alternative to
laboratory polysomnography to reduce the cost of MAD
treatment, and to improve the quality and consistency of
posttreatment patient care.
Keywords Sleepapnea.Sleepdisorderedbreathing.Home
monitoring.Mandibularadvancementdevice.Outcome
assessment
Introduction
Obstructive sleep apnea (OSA) is the most common disorder
observed in the practice of sleep medicine and is responsible
formoremortalityandmorbiditythananyothersleepdisorder
[1]. Although characterized over 40 years ago [2, 3], OSA
has only recently gained recognition as one of the world’s
most prevalent, underdiagnosed disorders [4, 5]. Due to
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public health concern [6]. The disorder is characterized by
frequent loud snoring and recurrent failures to breathe
adequately during sleep (termed apneas or hypopneas),
usually as a result of collapse of the upper airway.
Mandibular advancement devices (MADs) are being
increasingly recognized as a treatment alternative to
continuous positive airway pressure (CPAP), particularly
for patients with mild to moderate OSA [7–12]. MADs are
designed to protrude the mandible and thus the tongue and
epiglottis during sleep, preventing airway occlusion [13].
Comparisons of MAD to CPAP have revealed that although
MADs are less efficacious than CPAP in reducing the RDI
they are, on average, used more frequently, preferred by
more patients and more readily accepted than CPAP [14].
Recent studies demonstrated that both MADs and CPAP
can reduce the 24-h diastolic blood pressure by an average
of 3 mmHg after 4 weeks of treatment [15–17]. Similarly to
CPAP, self-reported improvements in quality of life and
decrease in sleepiness are reported in the majority of
patients [14].
The primary goal of this study was to use a self-applied
limited channel recorder to objectively assess the effective-
ness of MAD therapy when the dentist determined the
patient had reached the titration endpoint. A second goal
was to determine factors which might predict successful
treatment outcomes and provide a more refined method for
identifying patients who may be appropriate for MAD
therapy as the initial treatment option. Finally, we wanted to
demonstrate two potential models of collaboration between
the dentist and sleep medicine physician in monitoring
MAD treatment outcomes.
Materials and methods
Eleven females and 19 males were recruited from two dental
practices before treatment with an oral appliance and enrolled
in the study. Twenty-five of the patients had failed CPAP
therapy. After obtaining an informed consent (approved by the
BioMed IRB, San Diego, CA, USA) patients completed a
two-night pretreatment in-home study with the Apnea Risk
Evaluation System (ARES TM) Unicorder TM (Advanced
Brain Monitoring, Carlsbad, CA, USA). This pretreatment
recording was conducted between the time the dental
impressions were taken and when the TAP II Mandibular
Advancement Device (MAD) (Airway Management, Dallas,
TX, USA) was fabricated and ready for insertion.
The TAP is a custom-made oral appliance with separate
upper and lower appliances joined by a titration or
advancement mechanism on the upper and a transverse
bar or socket on the lower. The titration mechanism uses a
hook to engage the bar or socket on the lower once each
device is placed in the mouth. A jackscrew controls the
position of the hook and thus the amount of protrusion. The
patient can self-titrate the device using a removable hex key
which engages the screw.
On the day of insertion of the MAD, patients completed
the Beck depression index, Epworth sleepiness scale, and
the Flemons’ quality of life questionnaire. At the insertion
appointment, both study sites attempted to achieve a
starting MAD titration position whereby the patient could
just hook the lower tray with the upper tray using active
protrusion with both trays in place. In the rare occasion that
this level of advancement was not tolerated by the patient,
the starting protrusion was reduced. Patients were instructed
to begin adjusting the MAD in one-half turn increments as
soon as it was tolerable, until a cessation in snoring or the
symptoms had resolved. As a result, the titration endpoint
was determined by the dentist based on the patient’s self-
report. At the follow-up appointment, which was typically
scheduled 3 to 4 weeks subsequent to the MAD insertion,
the assessment questionnaires were completed again and
the ARES Unicorder study was repeated. Twenty-seven
of the 30 patients reached their endpoint within 34 days.
The other three patients completed their endpoint in 40, 61,
and 75 days; the delay in reaching the endpoint was due to
patient illness unrelated to this study.
In between the time that treatment was initiated and the
titration endpoint, each patient maintained a daily journal
that recorded the time the appliance was inserted each
night, and the time it was removed in the morning.
The pre- and posttreatment studies were conducted with
the ARES Unicorder. From a single site on the forehead,
the wireless recorder measures oxygen saturation, pulse
rate, airflow, respiratory effort, snoring levels, head move-
ment, and head position [18] (Fig. 1). Reflectance oximetry
is used to obtain the SpO2 and pulse rate signals.
Respiratory effort is derived from the measurement of
changes in forehead venous pressure acquired using a
combination of photoplethysmography and changes in
surface pressure of the forehead reflectance oximetry
sensor. Airflow is obtained via a cannula and nasal pressure
transducer. A calibrated acoustic microphone is used to
acquire quantified snoring levels (dB). Actigraphy is used
to measure head movement and derive head position. The
recorder was designed to be affixed by the patient, and
provide alerts during the study if poor quality airflow or
SpO2 is detected so the device could be adjusted.
The description and validation of this device in 284 valid
comparisons of the in-laboratory simultaneous PSG and
ARES and 187 valid comparisons of the in-laboratory PSG
with a separate two nights unattended self-applied ARES
Unicorder has been previously published [18]. Using a
diagnostic AHI cutoff of >10, the concurrent in-lab
comparison yielded a sensitivity of 97.4, a specificity of
140 Sleep Breath (2007) 11:139–14785.6, a positive predictive value of 93.6, and a negative
predictive value of 93.9. The in-home comparison sensitiv-
ity, specificity, positive predictive value, and negative
predictive value were 91.5, 85.7, 91.5, and 85.7, respec-
tively. The failure rate was 2%.
In an independent validation of 40 subjects (13 healthy
controls and 27 patients with symptoms of EDS and/or
snoring) using a clinical cut-off of 15, the sensitivity of the
ARES compared to concurrent PSG was 100% (25/25
patients) and specificity 67% (10/15 subjects). The sensitiv-
ity for two-nights of ARES in-home compared to the PSG
was 96%; specificity was 80%. The failure rate was 5% [19].
Automated scoring algorithms were applied off-line to
detect sleep disordered breathing. The AHI was computed
using a time-in-bed measure based on recording time with
acceptable signal quality minus periods when the patient
was upright or presumed to be awake based on actigraphy.
Apneas, based on a 10-s cessation of airflow detected by
the automated algorithms, were included in all apnea–
hypopnea indexes (AHI). Hypopnea events required a 50%
reduction and recovery in airflow and were further stratified
based on the depth of desaturation. The AHI-4% criteria
required a minimum 3.5% reduction in SpO2 and at least a
1.0% recovery. Hypopneas included in the AHI-3% and
AHI-1% criteria required SpO2 desaturation and resatura-
tion using stepped thresholds. For the AHI-3%, if the SpO2
at the point of maximum saturation before the event was
greater than or equal to 95% then a 2.2% reduction and a
2.2% recovery in SpO2 was required. For maximum
saturations of between 95–93% the required SpO2 change
was a 2.5% reduction and 2.5% recovery; between 93–91%
a 3.0% reduction and 2.7% recovery; between 91–88% a
3.5% reduction and 3.0% recovery; and below 88% a 4.0%
reduction and 3.5% recovery. For the AHI-1%, if the point
of maximum saturation before the event was greater than
93%, then a 1.0% reduction and 1.0% recovery was
required; and for events with a starting SpO2 between
93–91%, a 1.2% reduction and 1.2% recovery was
required. For an AHI-1% event to be called, the change in
flow and desaturation needed to be associated with a
behavioral arousal (i.e., an abrupt change in pulse rate,
snoring sound or a head movement). After the automated
scoring was applied, the full disclosure recordings were
visually inspected by a sleep medicine physician to confirm
the accuracy of the automated scoring, and to reclassify as
central and/or exclude autodetected events if necessary. At
the time of the review, the clinician was blinded to the
study status (i.e., pre- or posttreatment). The physiological
data, including AHI values, percent time with SpO2 below
90, 85, and 80%, and percentage time snoring greater than
30, 40, 50, and 60 dB were then calculated.
Responses to the Beck depression index and Flemons’
quality of life questionnaire were tallied in accordance with
published methods [20, 21].
Paired t tests were used to identify significant changes in
the pre- and posttreatment physiological data and question-
naire responses.
To identify anthropomorphic factors that may impact
MAD treatment outcomes, patients were stratified into
two groups. Group 1 included all patients with a post-
treatment AHI-4%≤5( n=18). The balance of patients with
an AHI-4%>5 were assigned to group 2 (n=12). Paired t
tests were used to identify significant group differences.
To develop and validate the prediction of the posttreatment
AHI using pretreatment data, patients were paired and
assignedintoeitherthemodeldevelopmentorcrossvalidation
group based on similarities in the pre- and post-4% AHI and
1% AHI. Correlation analysis was used to identify anthropo-
morphic variables and measures of obstructive breathing
before treatment which might be useful in estimating the
posttreatment 4% AHI (post-T 4%). Variableswithsignificant
correlations were then used in a linear regression to derive
predicted posttreatment values (predict AHI).
Results
Overall effects of MAD treatment The mean ± SD and
minimum pre- and posttreatment valid recording times were
9.6±3.6 and 3.5 h; and 10.3±2.4 and 4.6 h, respectively.
Pairedt tests revealed significant changes (p<0.001)inall
pre- vs posttreatment sleep disordered breathing measures,
including: apnea–hypopnea index with a 4% (AHI-4%) and
1% (AHI-1%) desaturation (Fig. 2).
A decrease in hypoxemia measures pre- and posttreat-
ment were also observed including the percentage of time
Fig. 1 Patient wearing a unicorder
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percentage change in SpO2 across all AHI events (% Dip)
(p<0.001) (see Fig. 3).
Significant reduction in the average snoring levels at 30
and 40 dB across the valid recording time were also
observed (p<0.001) (Fig. 4).
Based on conventional outcome measures, the MAD
therapy was highly efficacious. Twenty-seven of the 30
(90%) patients had a posttreatment AHI-4%<10 (Fig. 5a).
All but one patient (97%) exhibited at least a 50% decrease
in AHI-4% or had a posttreatment AHI-4%≤10.
Using an alternative measure of AHI-1% (used to
identify residual sleep disordered breathing/upper airway
resistance) 21 of the 30 patients (70%) had a posttreatment
AHI-1%≤15 (Fig. 5b). Eighty-seven percent (26 of 30) of
the patients exhibited at least a 50% decrease in AHI-1% or
had a posttreatment AHI-1%≤15.
Paired t tests applied to the pre- and posttreatment scores
revealed statistically significant differences for Beck de-
pression index, Flemons’ QOL, Epworth sleepiness score
(all at the p≤0.001 level) (Fig. 6). Seventy-six percent (23/
30) of the patients showed a decrease in Epworth score;
60% had an Epworth score reduction of three or more.
Seventy-three percent (22/30) of the patients reported a
posttreatment reduction in depression; 53% had a Beck
depression index score reduction of three or more. Eighty-
seven percent of the patients reported an increase in the
Flemons’ QOL index; 60% showed in improvement score
of one or greater. All patients reported some level of
subjective improvement on at least one of these subjective
measures.
The correlation between the posttreatment percentage
time snoring above 30 dB and the AHI-4% was computed
because snoring is a principal measure used to assess the
MAD titration endpoint. The results in Fig. 7 suggest that
snoring is a good predictor of outcome when objectively
measured.
Daily self-reported compliance for the MAD revealed
that out of a total of 693 nights in bed recorded across all
subjects, only 20 nights were reported as not wearing the
MAD. The mean usage per night was 7.34±1.3 h. Three
of the 30 patients had incomplete paperwork due to either
confusion on the part of the patient or problems in
collecting the paperwork at the study sites. Although all
three patients said that they had worn the MAD for the
duration of the study, there was no written record
available that allowed the investigators to assess compli-
ance/usage.
Factors that affect treatment outcomes Analysis of vari-
ance was used to compare demographic and anthropo-
morphic measures of patients who had a posttreatment
AHI-4%≤5 and those who did not respond optimally to
treatment (Table 1). Significant differences in the two
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142 Sleep Breath (2007) 11:139–147groups were observed in the body mass index (p<0.01),
weight (p<0.01), and neck circumference (p<0.02).
Prediction of successful treatment outcome Correlation
analysis was applied to the entire data set (n=30) identify
pretreatment variables that had a significant relationship
with the posttreatment AHI-4% (see Table 2).
Various combinations of variables were submitted to
linear regression using the model development data set in
an effort to predict the posttreatment AHI-4%. Limiting the
number of variables to four (due to the small sample size),
the variables AHI-4%, AHI-3%, AHI-1%, and percent time
snoring >30 dB resulted in an R
2 of 0.68. The coefficients
derived from the linear regression were applied to the
model development and cross-validation data sets.
Twenty-seven of the 30 patients had predict-AHI
suggesting a successful outcome would be attained using
a clinical cutoff post-T 4% AHI≤10 (Fig. 8). Two of the
three patients were accurately predicted as unable to
achieve a post-T AHI≤10. The Bland–Altman plots
comparing the predicted-AHI and posttreatment AHI
(Fig. 9) suggest a reasonable fit of the data given the small
sample size used for the model development and cross
validation data sets.
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breathing using: a AHI-4% desaturation and b AHI-1% desaturation
Table 1 Characteristics of group that was treated optimally and the
group that was not treated optionally with a MAD (mean + SE)
Treated optimally
post-T AHI-4%≤5
Did not treat optimally
post-T AHI-4%>5
Gender
Females 7 4
Males 11 8
Age (years) 48.3±2.5 50.9±3.4
BMI (kg/m)** 27.6±0.8 33.1±2.1
Weight (kg)** 84.4±3.0 100.2±5.0
Neck
circumference (cm)*
40.0±0.7 43.2±1.0
*p<0.05
**p<0.01
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Consecutive patients who were referred to the dentist for a
MAD were provided the opportunity to enroll in the study.
The only exclusion criteria applied were ages less than 18
or older than 70 years. The inclusion of 25 subjects who
had previously failed CPAP therapy contributed to the wide
OSA severity range: nine of the subjects (30%) were
considered to have severe OSA (i.e., AHI-4%≥30) and an
additional 30% were considered to have moderate OSA
(AHI-4%>15 and <30). Seventy-seven percent of the
patients (23/30) had at AHI-1%>25, a clinical cut-off
which was considered at least moderate.
In this study, a treatment efficacy rate for the MAD was
90% using an AHI-4% clinical cut-off of 10, and 97%
when a 50% reduction in AHI was included in determining
a successful outcome. Eighty-seven percent of the patients
showed improvement using an AHI-1% with a clinical cut-
off of 15 or a 50% reduction in AHI. Eighty percent of the
patients (24/30) had a posttreatment AHI-1%≤16.
A recent evidence-based review summarized results
from 87 published studies (over 2,000 patients evaluated)
including 15 Sackett Level I and Level II randomized
controlled trials [14]. Using a definition of treatment
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Fig. 9 Bland–Altman plot of the difference between the predicted
posttreatment AHI-4% vs the actual posttreatment AHI for a the
model development and b the cross validation groups
Table 2 Correlations between
posttreatment AHI-4% and
pretreatment measures
Pearson r (p<0.01) Pearson r (p<0.05)
Pretreatment 4% AHI r=0.53 Snoring >30 dB r=0.44
Pretreatment 3% AHI r=0.44 Neck circumference r=0.45
Pretreatment 1% AHI r=0.54 Body mass index r=0.45
Snoring >40 dB r=0.52 Weight r=0.45
% Time <90% SpO2 r=0.56
144 Sleep Breath (2007) 11:139–147success that required achieving a posttreatment respiratory
disturbance index below 10, success was achieved on
average across all studies for 52% of patients treated with
oral appliances. When the more liberal criteria of a 50%
reduction in RDI were applied to assess outcome, 65% of
patients were shown to have a positive result with MAD.
In an attempt to compare these previous finding to this
data set, a clinical cut-off of 10 was applied to the AHI-1%.
The differences between the AHI-1% and RDI include a
50% reduction in flow vs 30%; a 1% desaturation vs no
desaturation; arousal indicators based on changes in
snoring, pulse rate, and head movement vs cortical
arousals; and the use of time-in-bed vs total-sleep-time.
Using this alternative clinical cut-off, 33% of the patients
had a successful outcome. When a 50% reduction in AHI-
1% was included, 77% had a successful outcome. Results
are more consistent with the previous research.
The findings in this study were consistent with previous
reports which found self-reported improvements in quality
of life and decrease in sleepiness in the majority of patients
[14]. No effort was made in this study to obtain objective
measures of improvement. To date, only four studies have
utilized objective measures of alertness or neurocognitive
function to assess treatment outcomes with MAD therapy,
with mixed results [22–25]. Further investigations need to
be conducted to assess the effectiveness of MAD therapy in
ameliorating cognitive impairments in OSA.
The strong correlation (r=0.63) between posttreatment
% time snoring >30 dB and the posttreatment AHI-4%
suggests that the current clinical practice of relying on
residual snoring to asses MAD titration is valid. It is
interesting to note that there was no apparent correlation
between snoring levels and pretreatment AHI values. Given
the discrepancy between the self-reported and objectively
measured snoring at the titration endpoint, it appears that
the bed-partner or patient’s observation may not provide the
most accurate means for titrating a MAD.
Several studies have reported increased efficacy for MADs
in patients with supine positional OSA [7, 26]; however, the
association has not been widely confirmed. This is due in
part to the fact that the majority of studies on MAD therapy
do not report the number of abnormal respiratory events by
sleep position despite the recommendation of the ASDA
Practice Parameters for separate calculations of supine and
lateral RDIs [27, 28]. Supine positionality did not appear to
influence the treatment outcome in our study, possibly,
because there were so few MAD treatment failures. This
may be a result of the appliance which was used or that the
small sample size was not representative of the population
treated with oral appliances.
A recent evidence-based review reported that median
MAD treatment compliance across patients was 77% after
1 year [14]. In this study, compliance was only monitored
during the titration period which may have contributed to
the favorable finding (i.e., 97%). Other factors that may
have influenced this outcome were a relatively small
sample size and/or patient compensation being provided.
Given that 80% of the study participants were CPAP
failures, the influence of prior CPAP use on MAD
compliance should be explored. While an objective mea-
sure of MAD compliance would eliminate potential bias
contributed by self-reported use, practical methods are not
currently available.
The suggested decrease in MAD efficacy with increasing
body mass index (BMI) was confirmed [27, 28]. Weight
and neck circumference also appeared to influence the
posttreatment apnea/hypopnea index. These variables make
sense: the upper airway tends to be narrower in patients
with more fatty tissue around the neck and the additional
mass combines with gravity to contribute to greater
collapsibility when sleeping supine.
The successful treatment outcome of patients with severe
sleep apnea suggests that a more quantitative approach
should be investigated to identify candidates appropriate for
a MAD therapy. The results from the predictive model,
once fully validated, could provide the guidance needed for
sleep medicine physicians to recommend an oral appliance
as an initial treatment option for more severe patients.
Alternatively, substantial differences between the predicted
and actual posttreatment AHI could help dentists determine
when a patient has not been fully titrated.
Given the small sample size of the model development
data set (n=15), only four variables were included in the
regression model even though the correlations presented in
Table 2 suggested additional variables would be predictive.
It is expected that the error between the predicted and actual
posttreatment AHI can be reduced with larger data sets. In
addition to expanding the database used for the predictive
model, future investigations should be conducted to
determine if the accuracy of the predictive model is
influenced by the type of MAD.
Dentists represent an important access point for identi-
fying and treating patients with undiagnosed OSA. This
study was designed to demonstrate two models of collab-
oration between a dental sleep medicine specialist and a
sleep medicine physician. As recommended by the AASM,
only patients with mild to moderate OSA were offered
MAD therapy as the initial treatment choice in this study.
Patients with severe sleep apnea were enrolled only after
failure of CPAP therapy. In one model, the dentist referred
the patient to the sleep medicine physician and his staff to
obtain and review the pre- and posttreatment physiological
data. In the second model, the dentist acquired the data and
transmitted it to the sleep medicine physician for review. In
both models, the physical and history was made available to
the physician for interpretation of the data [29].
Sleep Breath (2007) 11:139–147 145A follow-up PSG is generally not affordable in cases
where it is not covered by an insurance company or health
ministry; sleep centers do not tend to offer less expensive
level III studies as an alternative. This creates a situation
whereby treatment outcomes are simply not assessed, or the
dentist conducts the study independently, without the
assistance or oversight of the sleep medicine professional.
Left on their own, many dentists rely upon oximetry and
other level IV devices to monitor treatment outcomes, in
part because of their limited experience in interpreting the
more sophisticated signals obtained by level III devices.
Although several level III devices have automated scoring
algorithms, the physiological data should still be reviewed
by a trained professional. In two patients, the review of the
full disclosure recording allowed recognition of complex
sleep apnea (i.e., central sleep apnea was revealed post-
treatment after the obstructive breathing was resolved)
suggesting the importance of having an experienced
professional review the data. This study suggests an
alternative approach for assessing MAD treatment out-
comes that is based on a collaborative relationship between
dentists and sleep medicine physician using a limited
channel recording system.
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